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ABSTRACT
Autoimmune pancreatitis has been associated with many syndromes in the presence of increased immunoglobulin levels. IgG4 antibodies 
are elevated in the context of lymphoplasmacytic sclerosing pancreatitis associated with IgG4-related disease. We present the case of a 
74-year-old man diagnosed with autoimmune pancreatitis on a cancer background. Awareness of this condition in the cancer patient is 
crucial for timely diagnosis. Infectious complications might have implications for the choice of immunosuppressant.
LEARNING POINTS
• Autoimmune pancreatitis can mimic pancreatic cancer, thus delaying diagnosis in patients with cancer. 
• It is important to rule out malignancy and distinguish autoimmune pancreatitis from pancreatic cancer, but obtaining a sample of 
pancreatic tissue can be difficult.
• Steroids are the mainstay of initial treatment, but there is growing evidence for the use of other immunomodulators, such as rituximab, 
for induction and maintenance or as an option for patients at high risk of relapse.
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INTRODUCTION
Autoimmune pancreatitis (AIP) is a chronic fibroinflammatory disease of the pancreas that belongs to the spectrum of immunoglobulin 
G-subclass 4-related diseases (IgG4-RD)[1]. Lymphoplasmacytic sclerosing pancreatitis (LPSP) typically presents with painless obstructive 
jaundice[1,2]. Pancreatic imaging, measurement of serum IgG4 levels, and determination of other organ involvement are all helpful for 
distinguishing AIP from pancreatic cancer[3,4]. LPSP is highly responsive to steroids, but immunomodulators should be included in induction 
therapy in patients who fulfil the severity criteria[2].
CASE DESCRIPTION
A 74-year-old Caucasian man presented to the outpatient clinic in May 2018 with painless obstructive jaundice. He had a history of stage 
IIA gastric cancer in 2013 (submitted to perioperative chemotherapy with six cycles of cisplatin+5-fluorouracil and total gastrectomy 
with complete pathological response) and also of non-muscle-invasive bladder cancer in 2017 (submitted to trans-urethral resection). 
Colangio-MRI was performed and showed a mass measuring 40×30×40 mm in the head of the pancreas and causing obstruction of the main 
pancreatic and biliary duct leading to dilatation of the biliary tree (Fig. 1A). Tumour markers (CEA, CA19.9) were normal. IgG4 levels were not 
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measured. A percutaneous pancreatic biopsy was performed since endoscopic ultrasonography was not feasible due to the surgical history. 
The specimen did not show any histological changes compatible with malignancy or inflammatory disease. A biliary stent was inserted. The 
patient was discharged with clinical and imaging re-evaluation scheduled within the following 3 months. 
Figure 1. Radiologic features of pancreatic lesion. – A – Colangio magnetic resonance imaging (CMRI) confirms the presence of a heterogeneous mass in the head of the 
pancreas, with decreased signal intensity on T1 weighted image. B - Computed tomographic (CT) scan shows a diffusely enlarged pancreas with a heterogeneous mass of 
about 60 mm of maximum dimeter in the head of the pancreas.
Shortly before the date of re-evaluation, the patient was admitted to hospital because of new-onset ascites, peripheral oedema and 
acute kidney injury. He was pale, thin and dehydrated, with a distended abdomen without palpable masses, and oedema below the knees. 
The laboratory work-up revealed normocytic/normochromic anaemia, hypoalbuminaemia, normal bilirubinaemia, increased alkaline 
phosphatase and aminotransferases, increased IgG4, acute kidney injury and hyponatraemia (Table 1). Diagnostic paracentesis showed no 
signs of infection or malignancy. The abdominal CT scan showed an increase in the size of the pancreatic mass and portal vein thrombosis 
(Fig. 1B). Percutaneous biopsy was repeated and showed lymphoplasmacytic foci, marked storiform fibrosis, CD138 positivity and IgG4 
expression (Fig. 2). 
Variable Reference range 1st Hospital
admission
After 4 weeks
of steroids
After tapering 2nd Admission, 
day 12
H a e m o g l o b i n 
(g/dL)
13–18 9.6 11.5 13.8 13.0
Platelets (mm3) 150,000–400,000 190,000 267,000 114,000 166,000
Leucocytes (mm3) 4.500–11,000 11,400 11,500 11,800 12,300
Urea (mg/dl) 10–50 27 14 75 137
Creatinine (mg/dl) 0.5–1.2 2.73 0.8 1.4 2.4
Sodium (mmol/l) 135–150 133 139 131 133
Potassium 
(mmol/l)
3.5–5.3 4.8 4.0 4.7 5.5
Albumin (g/dl) 3.5–5.0 2.0 3.1 2.7 2.7
Bilirubin (mg/dl) ≤1.0 0.6 1.0 0.7 0.9
ALP (U/l) ≤117 246 108 156 181
AST (U/l) ≤38 89 24 42 49
ALT (U/l) ≤41 59 19 27 25
GGT (U/l) 11–49 547 228 187 171
INR ≤1.20 1.69 1.33 1.82 1.63
IgG4 39.2–864.0 2248 1379.5 952.7 – Table 1. Laboratory findings
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The diagnosis of LPSP was established and the patient started treatment with steroids (40 mg/day) and anticoagulation for the portal vein 
thrombosis. During his hospital admission, the patient developed Escherichia coli bacteraemia that first manifested as cholangitis, which 
required intravenous antibiotics. The patient responded partially to the treatment (his IgG4 level dropped to 1379) and a first attempt 
at steroid tapering was made. However, the patient deteriorated clinically and had to be readmitted to hospital. The dose of steroids was 
increased to 40 mg/day with no improvement. The patient’s clinical situation rapidly declined due to severe sepsis which started as another 
episode of cholangitis. There was no response to broad-spectrum intravenous antibiotics and the patient died on day 12. 
DISCUSSION
LPSP is the pancreatic manifestation of systemic IgG4-RD. The typical patient with LPSP is over 60–70 years of age, with male predominance 
(3:1)[2]. Other clinical presentations include a pancreatic mass on imaging, focal or diffuse pancreatic enlargement, pancreatic ductal 
strictures and rarely, acute pancreatitis[2]. The clinical presentation can mimic other types of pancreatitis and pancreatic cancer[4]. The 
incidence of malignancy in patients with IgG4-RD is similar to that observed in the general population. However, the incidence of AIP in 
patients with cancer is unknown and hard to establish particularly because of the difficulties of diagnosis. 
Patients with LPSP most commonly present with a cholestatic pattern of liver enzyme elevation and raised IgG4 levels (>2 times the upper 
limit of normal). The diagnosis of LPSP is based on histological and imaging findings. The key histological finding is lymphoplasmacytic 
infiltration rich in IgG4-positive plasma cells combined with storiform fibrosis and obliterative phlebitis[5]. Imaging studies show a diffusely 
enlarged gland with featureless borders and delayed enhancement with/without a capsule-like rim[2]. In our case, the diagnosis was delayed 
mainly due to lack of awareness of this condition and the high probability of malignancy. Consequently, treatment with steroids was delayed 
for 3 months when there was decompensated cholestatic hepatic disease.
Steroids are a cornerstone in the management of LPSP. Most patients show remarkable initial improvement with prednisone administration 
as shown by a decrease in liver enzymes. The recommended regimen is prednisone 40 mg/day for 4 weeks, and slow tapering by 5 mg/week 
after evaluation of clinical, radiological and serological response. Other immunosuppressant therapy, such as rituximab, might be considered 
for induction in patients with risk factors for relapse: proximal biliary involvement, younger age and high alkaline phosphatase. Our patient 
had two criteria for the use of rituximab and his disease was refractory to therapy with steroids. However, infectious complications precluded 
the use of this B-cell depletion therapy. 
The diagnosis of LPSP is difficult, particularly in the cancer patient, where the diagnostic assessment is sometimes simplified and the 
therapeutic intervention tailored for symptom management. Higher awareness of the diagnosis could have resulted in earlier introduction 
of steroid therapy in our patient. Stratifying the risk for relapsing disease is mandatory. Infectious complications commonly limit therapeutic 
intervention in these patients. 
Figure 2. Histopathological features of IgG4-related pancreatitis. The biopsy specimen from the pancreas indicated IgG4-related pancreatitis. (A) Infiltrate of lymphocytes, plasma 
cells, eosinophils and fibroblasts (long arrow); storiform fibrosis pattern, often likened to a cartwheel with bands of fibrosis (**) emanating from the centre (*) and resembling 
the spokes of a wheel: in this case the pattern is incomplete; obliterative phlebitis (arrow heads) (haematoxylin and eosin, 20×). (B) Plasma cell infiltrates positive for CD138 
compatible with IgG4-producing clones (immunohistochemistry for CD138)
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